Back to Search
Start Over
In vivo dose finding of tariquidar using (R)-[11C]verapamil µPET.
- Source :
- BMC Pharmacology; 2007 Supplement 2, Vol. 7, Special section p1-1, 1p
- Publication Year :
- 2007
-
Abstract
- Introduction Tariquidar (TQD, Xenova, UK) is a third-generation inhibitor of the multidrug efflux transporter P-glycoprotein (P-gp) with potential applications in neurology and oncology in order to increase drug exposure of tissues targeted for treatment. We used small-animal positron emission tomography (µPET) with the P-gp substrate (R)-[<superscript>11</superscript>C]verapamil (VPM) in order to measure in vivo the degree of P-gp inhibition at the rat blood-brain barrier (BBB) after administration of different doses of TQD. Methods Wistar Unilever rats received intravenous doses of 0, 1, 3, 5, 7.5 and 15 mg/kg of TQD followed by a 1-hour VPM µPET scan recorded at 2 hours after TQD administration. Brain-to-plasma radioactivity ratios were fitted to a sigmoidal dose-response curve. Results TQD inhibited P-gp-mediated efflux of VPM across the BBB with an apparent half-maximum effective dose (ED<subscript>50</subscript>) of 6.6 mg/kg (95% confidence interval: 4.9-8.2 mg/kg) which was in good agreement with previous data reported in mice for another P-gp substrate (loperamide, ED<subscript>50</subscript>: 5.7 mg/kg) [1]. Brain-to-plasma radioactivity ratios after 0 and 15 mg/kg of TQD were 0.23 and 3.15, respectively. Conclusion Our data suggest that TQD is a potent inhibitor of P-gp at the rat BBB. Moreover, VPM PET appears to be a useful tool for in vivo dose finding of novel P-gp inhibitors in animals and humans. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14712210
- Volume :
- 7
- Database :
- Complementary Index
- Journal :
- BMC Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 35702521
- Full Text :
- https://doi.org/10.1186/1471-2210-7-S2-A22